This study investigates the application of melt extrusion for the development of an oral retard formulation with a precise drug release over time. Since adjusting the formulation appears to be of the utmost importance in achieving the desired drug release patterns, different formulations of laminar extrudates were prepared according to the principles of Experimental Design, using a design for mixtures to assess
the influence of formulation composition on the in vitro drug release from the extrudates after 1 h and after 8 h. The effect of each component on the two response variables was also studied.
Ternary mixtures of theophylline (model drug), monohydrate lactose and microcrystalline wax (as
thermoplastic binder) were extruded in a lab scale vertical ram extruder in absence of solvents at a temperature
below the melting point of the binder (so that the crystalline state of the drug could be maintained),
through a rectangular die to obtain suitable laminar systems.
Thanks to the desirability approach and a reliability study for ensuring the quality of the formulation, a
very restricted optimal zone was defined within the experimental domain. Among the mixture components,
the variation of microcrystalline wax content played the most significant role in overall influence
on the in vitro drug release. The formulation theophylline:lactose:wax, 57:14:29 (by weight), selected
based on the desirability zone, was subsequently used for in vivo studies. The plasma profile, obtained
after oral administration of the laminar extruded system in hard gelatine capsules, revealed the typical
trend of an oral retard formulation.
The application of the mixture experimental design associated to a desirability function permitted to
optimize the extruded system and to determine the composition space that ensures final product quality.
2015 Elsevier B.V. All rights reserved.
